Trials
Search / Trial NCT06416475

The Effect of Mankai on Glycemic Control Among Patients With T2D

Launched by BEN-GURION UNIVERSITY OF THE NEGEV · May 15, 2024

Trial Information

Current as of February 19, 2025

Active, not recruiting

Keywords

Clinical Trial Diabetes Mellitus, Type 2 Nutritional Intervention Mankai Duckweed Wolffia Globosa Polyphenols

ClinConnect Summary

Type 2 diabetes (T2D), most commonly stemming from sustained obesity, adiposity, and a sedentary lifestyle, is strongly associated with increased cardiovascular risk. Glycated hemoglobin A1c (HbA1c), reflecting glycemic control, is tightly related to cardiovascular risk. In the recent decade, several antihyperglycemic medications have been shown to modify cardiovascular risk among patients with established cardiovascular disease. Maintaining a healthy diet, preferably a Mediterranean-like diet, rich in plant-based protein and low in meat products, is the first-line intervention to promote g...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \> 30 years
  • A formal diagnosis of T2D (126mg/dl fasting glucose or higher, or HbA1c\>6.5%) or taking T2D medications with HbA1c levels over 7%
  • Medication stability for at least 3 months prior to Intervention initiation
  • Adherence to medical follow-up in primary care clinic or diabetes-centered outpatient services
  • Exclusion Criteria:
  • HbA1c lower than 7% or higher than 10%
  • Known insulinopenia
  • Treatment with coumadin (warfarin)
  • Advanced renal failure
  • Significantly disturbed liver enzymes (liver transaminases or bilirubin levels more than time three upper-normal-limit)
  • A significant illness that might require hospitalization
  • Regular Mankai consumption
  • State of pregnancy or lactation
  • Presence of active cancer or chemotherapy treatment in last three years
  • Participation in another trial

Trial Officials

Idit Liberty

Principal Investigator

Soroka University Medical Center

Iris Shai

Study Director

Ben-Gurion University of the Negev

About Ben Gurion University Of The Negev

Ben-Gurion University of the Negev (BGU) is a leading research institution located in Israel, dedicated to advancing knowledge and innovation in various fields, including health sciences, engineering, and environmental studies. With a strong emphasis on interdisciplinary collaboration, BGU fosters a dynamic research environment that integrates academic excellence with practical applications. The university is committed to addressing global challenges through cutting-edge clinical trials and studies, leveraging its expertise to improve healthcare outcomes and contribute to the advancement of medical science. BGU’s robust infrastructure and partnerships with industry and healthcare organizations position it as a pivotal player in the field of clinical research.

Locations

Be'er Sheva, , Israel

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0